Atlas Trials

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

Clinical trial NCT07520214 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT07520214
Sponsor
Beijing Neurosurgical Institute
Status
ENROLLING_BY_INVITATION
Phase
Early Phase 1
Study type
INTERVENTIONAL
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGlioblastom WHO Grade 4
Start date
2025-09-10
Primary completion
2027-12-31
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.